Comment on alemtuzumab and inclusion body myositis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Biologic therapy in the idiopathic inflammatory myopathies.Rheumatology international · 2020
   Review
2. Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken.Acta neuropathologica · 2015
   Review
3. Emerging therapeutic options for sporadic inclusion body myositis.Therapeutics and clinical risk management · 2015
   Review
4. Th1 response and systemic treg deficiency in inclusion body myositis.PloS one · 2014
   Article
5. Targeted immunotherapy trials for idiopathic inflammatory myopathies.Journal of neurology · 2013
   Review
6. [Therapeutic monoclonal antibodies in clinical neurology].Der Nervenarzt · 2010
   Review

Corrections and comments

• Comment on
  Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.2009

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as